NVP-BGT226PI3K/mTOR inhibitor,selective and novel CAS# 1245537-68-1 |
- IPI-145 (INK1197)
Catalog No.:BCC1104
CAS No.:1201438-56-3
- IC-87114
Catalog No.:BCC1161
CAS No.:371242-69-2
- PI-103
Catalog No.:BCC1162
CAS No.:371935-74-9
- PIK-75
Catalog No.:BCC1163
CAS No.:372196-77-5
- TGX-221
Catalog No.:BCC1244
CAS No.:663619-89-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1245537-68-1 | SDF | Download SDF |
PubChem ID | 57336745 | Appearance | Powder |
Formula | C32H29F3N6O6 | M.Wt | 650.6 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in DMSO > 10 mM | ||
Chemical Name | (Z)-but-2-enedioic acid;8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-piperazin-1-yl-3-(trifluoromethyl)phenyl]imidazo[4,5-c]quinolin-2-one | ||
SMILES | CN1C2=CN=C3C=CC(=CC3=C2N(C1=O)C4=CC(=C(C=C4)N5CCNCC5)C(F)(F)F)C6=CN=C(C=C6)OC.C(=CC(=O)O)C(=O)O | ||
Standard InChIKey | YUXMAKUNSXIEKN-BTJKTKAUSA-N | ||
Standard InChI | InChI=1S/C28H25F3N6O2.C4H4O4/c1-35-24-16-33-22-6-3-17(18-4-8-25(39-2)34-15-18)13-20(22)26(24)37(27(35)38)19-5-7-23(21(14-19)28(29,30)31)36-11-9-32-10-12-36;5-3(6)1-2-4(7)8/h3-8,13-16,32H,9-12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1- | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | BGT226 (NVP-BGT226) is a novel inhibitor of class I PI3K/mTOR with IC50 values of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ, respectively. | |||||
Targets | PI3Kα | PI3Kγ | PI3Kβ | |||
IC50 | 4 nM | 38 nM | 63 nM |
NVP-BGT226 Dilution Calculator
NVP-BGT226 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.537 mL | 7.6852 mL | 15.3704 mL | 30.7409 mL | 38.4261 mL |
5 mM | 0.3074 mL | 1.537 mL | 3.0741 mL | 6.1482 mL | 7.6852 mL |
10 mM | 0.1537 mL | 0.7685 mL | 1.537 mL | 3.0741 mL | 3.8426 mL |
50 mM | 0.0307 mL | 0.1537 mL | 0.3074 mL | 0.6148 mL | 0.7685 mL |
100 mM | 0.0154 mL | 0.0769 mL | 0.1537 mL | 0.3074 mL | 0.3843 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
BGT226 (NVP-BGT226) is a novel inhibitor of PI3K/mTOR for PI3Kα/β/γ with IC50 of 4 nM/63 nM/38 nM. [1]
The phosphatidylinositol-3-kinase (PI3K) pathway is one of the most commonly activated signaling pathways in pancreatic cancer and is a target of interest for new therapeutic approaches.
NVP-BGT226 is a novel dual class PI3K/mammalian target of rapamycin (mTOR) inhibitor. When used NVP-BGT226, cell viability decreased within 24-72 h after exposure to about 50% compared to untreated control cells in a concentration- but not time-dependent manner. [1] The dual PI3K/mTOR inhibitor NVP-BGT226 induces G0/G1 arrest and acts partially via downregulation of Survivin. NVP-BGT226 potently inhibited growth activity of cell lines, including SCC4, TU183 and KB cell lines with the IC50 ranging from 7.4 to 30.1 nM. [2]
In a FaDu cell xenografted mouse model, BGT226 inhibited tumor growth in a dose-dependent manner in a FaDu cell xenografted mouse model. Oral administration of BGT226 at 2.5 and 5 mg/kg for 3 weeks caused 34.7% and 76.1% reduction of the tumor growth on day 21, respectively (compared with control). BGT226 displayed comparable inhibition against tumor growth to rapamycin. The final volume of both groups was significantly smaller than those treated with LY294002 or the control. [2]
References:
[1]. Glienke, W, et al. The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines. TUMOR BIOLOGY, 2014, 33(3): 757-765.
[2]. Chang KY, et al. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Cancer Res, 2011, 17(22): 7116-7126.
- Glucocorticoid receptor agonist
Catalog No.:BCC1596
CAS No.:1245526-82-2
- PI4KIII beta inhibitor 3
Catalog No.:BCC1310
CAS No.:1245319-54-3
- 16-Oxoalisol A
Catalog No.:BCN3460
CAS No.:124515-98-6
- Retusin
Catalog No.:BCN7794
CAS No.:1245-15-4
- 2,2'-Bicinchoninic acid
Catalog No.:BCC8487
CAS No.:1245-13-2
- 16R-sitsirikine
Catalog No.:BCN3492
CAS No.:1245-00-7
- VU 0364739 hydrochloride
Catalog No.:BCC7875
CAS No.:1244640-48-9
- CGS 21680 HCl
Catalog No.:BCC4316
CAS No.:124431-80-7
- Cannabidiolic acid
Catalog No.:BCN6127
CAS No.:1244-58-2
- MG 149
Catalog No.:BCC5149
CAS No.:1243583-85-8
- 9-(1H-Benzotriazol-1-ylmethyl)-9H-carbazole
Catalog No.:BCC8792
CAS No.:124337-34-4
- Lenalidomide hydrochloride
Catalog No.:BCC1697
CAS No.:1243329-97-6
- GR 79236
Catalog No.:BCC7215
CAS No.:124555-18-6
- ent-Labda-8(17),13Z-diene-15,16,19-triol 19-O-glucoside
Catalog No.:BCN1598
CAS No.:1245636-01-4
- Brain natriuretic peptide (1-32) (human)
Catalog No.:BCC6034
CAS No.:124584-08-3
- Daidzin 6'-O-malonate
Catalog No.:BCN8245
CAS No.:124590-31-4
- TC-A 2317 hydrochloride
Catalog No.:BCC2418
CAS No.:1245907-03-2
- 2-Methyl-4-(2-methylbutyryl)phloroglucinol
Catalog No.:BCN7175
CAS No.:124598-11-4
- 6-O-Benzoylphlorigidoside B
Catalog No.:BCN6128
CAS No.:1246012-24-7
- 6-O-trans-Cinnamoylphlorigidoside B
Catalog No.:BCN6129
CAS No.:1246012-25-8
- 6-O-trans-p-Coumaroylshanzhiside methyl ester
Catalog No.:BCN1597
CAS No.:1246012-26-9
- 4'-O-trans-p-Coumaroylmussaenoside
Catalog No.:BCN6130
CAS No.:1246012-27-0
- Methyl (2R,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-3-phenylpropionate
Catalog No.:BCN8363
CAS No.:124605-42-1
- VU 0364439
Catalog No.:BCC1239
CAS No.:1246086-78-1
The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells.[Pubmed:26003166]
Oncotarget. 2015 Jul 10;6(19):17147-60.
Hepatocellular carcinoma (HCC) is one of the most common lethal human malignancies worldwide and its advanced status is frequently resistant to conventional chemotherapeutic agents and radiation. We evaluated the cytotoxic effect of the orally bioavailable dual PI3K/mTOR inhibitor, NVP-BGT226, on a panel of HCC cell lines, since hyperactivated PI3K/Akt/mTOR signaling pathway could represent a biomolecular target for Small Inhibitor Molecules in this neoplasia. We analyzed the drug activity in both normoxia and hypoxia conditions, the latter playing often a relevant role in the induction of chemoresistance and angiogenesis.In normoxia NVP-BGT226 caused cell cycle arrest in the G0/G1 phase of the cell cycle, induced apoptosis and autophagy at low concentrations. Interestingly the drug inactivated p-Akt and p-S6 at < 10 nM concentration.In hypoxia NVP-BGT226 maintained its cytotoxic efficacy at the same concentration as documented by MTT assays and Western blot analysis. Moreover, the drug showed in hypoxia inhibitory properties against angiogenesis by lowering the expression of the transcription factor HIF-1alpha and of VEGF.Our results indicate that NVP-BGT226 has a potent cytotoxic effect on HCC cell lines also in hypoxia condition, thus emerging as a potential candidate for cancer treatment in HCC targeted therapy.
The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines.[Pubmed:22170433]
Tumour Biol. 2012 Jun;33(3):757-65.
The phosphatidylinositol-3-kinase (PI3K) pathway is one of the most commonly activated signaling pathways in pancreatic cancer and is a target of interest for new therapeutic approaches. NVP-BGT226 is a novel dual class PI3K/mammalian target of rapamycin (mTOR) inhibitor that has entered Phase I/II clinical trials. We analyzed the effect of NVP-BGT226 (10-100 nM) on the pancreatic cell lines Panc-1, BxPc-3, AsPC-1 and MiaPaCa-2 in regard to cell viability, induction of apoptosis, cell cycle, and expression of the antiapoptotic genes Survivin, MCL-1, BCL-2 and BCL-xL. Cell viability decreased within 24-72 h after exposure to about 50% compared to untreated control cells in a concentration- but not time-dependent manner. Cell cycle analysis revealed that NVP-BGT226 induced predominantly G0/G1 cell cycle arrest. Additionally, real-time RT-PCR and Western blot analysis showed a remarkable decrease of Survivin expression. Originally designed as a dual inhibitor, there was only a significant inhibition of p-mTOR. In summary, the dual PI3K/mTOR inhibitor NVP-BGT226 induces G0/G1 arrest and acts, at least, partially via downregulation of Survivin.
NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.[Pubmed:22452803]
Radiat Oncol. 2012 Mar 27;7:48.
BACKGROUND: The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is activated in tumor cells and promotes tumor cell survival after radiation-induced DNA damage. Because the pathway may not be completely inhibited after blockade of PI3K itself, due to feedback through mammalian target of rapamycin (mTOR), more effective inhibition might be expected by targeting both PI3K and mTOR inhibition. MATERIALS AND METHODS: We investigated the effect of two dual PI3K/mTOR (both mTORC1 and mTORC2) inhibitors, NVP-BEZ235 and NVP-BGT226, on SQ20B laryngeal and FaDu hypopharyngeal cancer cells characterised by EGFR overexpression, on T24 bladder tumor cell lines with H-Ras mutation and on endothelial cells. Analysis of target protein phosphorylation, clonogenic survival, number of residual gammaH2AX foci, cell cycle and apoptosis after radiation was performed in both tumor and endothelial cells. In vitro angiogenesis assays were conducted as well. RESULTS: Both compounds effectively inhibited phosphorylation of Akt, mTOR and S6 target proteins and reduced clonogenic survival in irradiated tumor cells. Persistence of DNA damage, as evidenced by increased number of gammaH2AX foci, was detected after irradiation in the presence of PI3K/mTOR inhibition, together with enhanced G2 cell cycle delay. Treatment with one of the inhibitors, NVP-BEZ235, also resulted in decreased clonogenicity after irradiation of tumor cells under hypoxic conditions. In addition, NVP-BEZ235 blocked VEGF- and IR-induced Akt phosphorylation and increased radiation killing in human umbilical venous endothelial cells (HUVEC) and human dermal microvascular dermal cells (HDMVC). NVP-BEZ235 inhibited VEGF-induced cell migration and capillary tube formation in vitro and enhanced the antivascular effect of irradiation. Treatment with NVP-BEZ235 moderately increased apoptosis in SQ20B and HUVEC cells but not in FaDu cells, and increased necrosis in both tumor and endothelial all cells tumor. CONCLUSIONS: The results of this study demonstrate that PI3K/mTOR inhibitors can enhance radiation-induced killing in tumor and endothelial cells and may be of benefit when combined with radiotherapy.
Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.[Pubmed:23705826]
Mol Cancer. 2013 May 24;12:46.
BACKGROUND: Dysregulation of the PI3Kinase/AKT pathway is involved in the pathogenesis of many human malignancies. In acute leukemia, the AKT pathway is frequently activated, however mutations in the PI3K/AKT pathway are uncommon. In some cases, constitutive AKT activation can be linked to gain-of-function tyrosine kinase (TK) mutations upstream of the PI3K/AKT pathway. Inhibitors of the PI3K/AKT pathway are attractive candidates for cancer drug development, but so far clinical efficacy of PI3K inhibitors against various neoplasms has been moderate. Furthermore, specific MTORC1 inhibitors, acting downstream of AKT, have the disadvantage of activating AKT via feed-back mechanisms. We now evaluated the antitumor efficacy of NVP-BGT226, a novel dual pan-PI3K and MTORC1/2 inhibitor, in acute leukemia. METHODS: Native leukemia blasts were stained to analyze for AKT phosphorylation levels on a flow cytometer. Efficacy of NVP-BGT226 in comparison to a second dual inhibitor, NVP-BEZ235, was determined with regard to cellular proliferation, autophagy, cell cycle regulation and induction of apoptosis in in vitro and ex vivo cellular assays as well as on the protein level. An isogenic AKT-autoactivated Ba/F3 model, different human leukemia cell lines as well as native leukemia patient blasts were studied. Isobologram analyses were set up to calculate for (super) additive or antagonistic effects of two agents. RESULTS: We show, that phosphorylation of AKT is frequently augmented in acute leukemia. NVP-BGT226 as well as NVP-BEZ235 profoundly and globally suppress AKT signaling pathways, which translates into potent antiproliferative effects. Furthermore, NVP-BGT226 has potent proapoptotic effects in vitro as well as in ex vivo native blasts. Surprisingly and in contrast, NVP-BEZ235 leads to a profound G1/G0 arrest preventing significant induction of apoptosis. Combination with TK inhibitors, which are currently been tested in the treatment of acute leukemia subtypes, overcomes cell cycle arrest and results in (super)additive proapoptotic effects for NVP-BGT226--but also for NVP-BEZ235. Importantly, mononuclear donor cells show lower phospho-AKT expression levels and consequently, relative insensitivity towards dual PI3K-MTORC1/2 inhibition. CONCLUSIONS: Our data suggest a favorable antileukemic profile for NVP-BGT226 compared to NVP-BEZ235--which provides a strong rationale for clinical evaluation of the dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.